Vycor Medical, Inc. (OTCQB: VYCO) reported a 19% decline in revenue for the three months ended September 30, 2026, compared with the same period a year earlier, according to the company's financial results released via NEWMEDIAWIRE. The Boca Raton, Florida-based company, which operates through its Vycor Medical surgical device unit and its NovaVision vision-rehabilitation business, generated total revenue of $414,895 in the quarter, down from $513,792 in 2025. The Vycor Medical division, which produces the ViewSite Brain Access System (VBAS), saw revenue fall 18% to $402,048, a decrease of $90,054. The company attributed the decline largely to unusually high U.S. sales in the 2025 period, when it added new hospitals and received bulk orders from existing customers. International sales increased for the quarter, though management noted that international orders can be lumpy, with large purchases sometimes falling in different periods. Despite the revenue decline, Vycor Medical remained profitable on an operating basis, posting operating profit of $27,424 for the quarter, down from $32,085 a year earlier. For the nine-month period, operating profit rose to $80,083 from $70,425. Non-GAAP operating profit, which excludes non-cash depreciation and stock-based compensation, was $43,011 for the quarter and $125,751 for the nine months.
The more significant development for investors and the medical community may be the continued clinical validation of VBAS. During 2026, four new peer-reviewed studies were published on the device, bringing the total to 54 peer-reviewed clinical papers, plus 14 other clinical papers. One study was a case report on a complex pediatric tumor that highlighted the effectiveness of integrating neuro-navigation systems with VBAS as a paramount strategy for surgical resection. Another retrospective study of 23 patients found significantly fewer new neurological deficits at follow-up when VBAS was used compared with traditional blade retractors, implying safer tumor removal. A third paper, a single-center study of 29 adults, concluded that minimally invasive tubular resection using VBAS enables effective decompression of relatively large posterior fossa metastases with low cerebrospinal fluid diversion rates. The most recent paper described two cases in Japan of intracerebral hemorrhage evacuation using VBAS with an exoscope, noting that the device provided a stable corridor with sufficient visualization and working space to achieve deep hemostasis with familiar microsurgical instruments. These findings matter because they provide independent evidence that VBAS can reduce tissue damage and improve outcomes, which could support adoption in the more than 350 U.S. hospitals already using the system and in international markets.
The NovaVision division, which remains in development, posted revenue of $12,847 for the quarter, a 41% increase over the prior-year period, and $47,986 for the nine months, up 11%. NovaVision offers therapy programs for patients recovering from visual disorders after stroke or brain injury, including Visual Restoration Therapy, which the company describes as the only commercialized FDA-cleared therapy for vision rehabilitation following neurological brain damage. For a closer look at the surgical device, the company provides a VBAS Video and a NovaVision Video. More information is available at www.vycormedical.com, www.vycorvbas.com and www.novavision.com. The full release can be found at www.newmediawire.com.
